Literature DB >> 12573747

Intensity-modulated radiotherapy following extrapleural pneumonectomy for the treatment of malignant mesothelioma: clinical implementation.

Kenneth M Forster1, W Roy Smythe, George Starkschall, Zhongxing Liao, Tsuyoshi Takanaka, Jason F Kelly, Ara Vaporciyan, Anesa Ahamad, Lei Dong, Mohammad Salehpour, Ritsuko Komaki, Craig W Stevens.   

Abstract

PURPOSE: New insight into the extent of the target volume for the postoperative irradiation of malignant pleural mesothelioma as determined during surgery has indicated that standard conformal radiotherapy (IMRT) is not sufficient for curative treatment. We describe a novel technique for implementing intensity-modulated radiotherapy (IMRT) to deliver higher doses to treat the full extent of these complex target volumes. METHODS AND MATERIALS: After extrapleural pneumonectomy, 7 patients underwent simulation, treatment planning, and treatment with IMRT to the involved hemithorax and adjacent abdomen. The target volumes encompassed the entire operative bed, including the ipsilateral mediastinum, anterior pleural reflection, and ipsilateral pericardium and the insertion of the diaphragm and crura. These were extensively marked during surgery with radiopaque markers to facilitate target delineation.
RESULTS: Setup uncertainty and respiratory-dependent motion were found to be small. Coverage of the planning target volume was very good, with the crus of the diaphragm the most difficult volume to irradiate. The radiation doses to normal structures were acceptable.
CONCLUSION: IMRT for treatment of malignant mesothelioma after extrapleural pneumonectomy results in more potentially curative doses to large, complex target volumes with acceptable doses to normal tissues. Copyright 2003 Elsevier Science Inc.

Entities:  

Mesh:

Year:  2003        PMID: 12573747     DOI: 10.1016/s0360-3016(02)04150-0

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  15 in total

1.  Extra-pleural pneumonectomy in the era of image-guided intensity-modulated radiotherapy.

Authors:  Marco Trovo; Davide Franceschini; Carlo Furlan; Francesca Pietrobon; Stefano Vagge; Eleonora Farina; Alberto Revelant; Luca Visani; Virginia Maragna; Giuseppe Parisi; Vieri Scotti
Journal:  Radiol Med       Date:  2019-04-08       Impact factor: 3.469

2.  Adjuvant intensity-modulated proton therapy in malignant pleural mesothelioma. A comparison with intensity-modulated radiotherapy and a spot size variation assessment.

Authors:  S Lorentini; M Amichetti; L Spiazzi; S Tonoli; S M Magrini; F Fellin; M Schwarz
Journal:  Strahlenther Onkol       Date:  2012-02-10       Impact factor: 3.621

3.  Current therapies for malignant pleural mesothelioma.

Authors:  Takashi Nakano
Journal:  Environ Health Prev Med       Date:  2008-02-28       Impact factor: 3.674

Review 4.  What is the role of radiotherapy in malignant pleural mesothelioma?

Authors:  Allan Price
Journal:  Oncologist       Date:  2011-02-23

Review 5.  Adjuvant, neoadjuvant, and definitive radiation therapy for malignant pleural mesothelioma.

Authors:  Gwendolyn Cramer; Charles B Simone; Theresa M Busch; Keith A Cengel
Journal:  J Thorac Dis       Date:  2018-08       Impact factor: 2.895

6.  Phase II Study of Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) As Part of Lung-Sparing Multimodality Therapy in Patients With Malignant Pleural Mesothelioma.

Authors:  Andreas Rimner; Marjorie G Zauderer; Daniel R Gomez; Prasad S Adusumilli; Preeti K Parhar; Abraham J Wu; Kaitlin M Woo; Ronglai Shen; Michelle S Ginsberg; Ellen D Yorke; David C Rice; Anne S Tsao; Kenneth E Rosenzweig; Valerie W Rusch; Lee M Krug
Journal:  J Clin Oncol       Date:  2016-06-20       Impact factor: 44.544

7.  Advances in malignant pleural mesothelioma therapy: targeting EphA2 a novel approach.

Authors:  Najmunnisa Nasreen; Nazli Khodayari; Kamal A Mohammed
Journal:  Am J Cancer Res       Date:  2012-02-15       Impact factor: 6.166

8.  Intensity-Modulated Radiation Therapy Improves the Target Coverage Over 3-D Planning While Meeting Lung Tolerance Doses for All Patients With Malignant Pleural Mesothelioma.

Authors:  Sukran Ulger; Eren Cetin; Serap Catli; Hilal Sarac; Diclehan Kilic; Huseyin Bora
Journal:  Technol Cancer Res Treat       Date:  2016-11-15

Review 9.  New era of radiotherapy: an update in radiation-induced lung disease.

Authors:  M F K Benveniste; J Welsh; M C B Godoy; S L Betancourt; O R Mawlawi; R F Munden
Journal:  Clin Radiol       Date:  2013-03-06       Impact factor: 2.350

Review 10.  Management options for malignant pleural mesothelioma: clinical and cost considerations.

Authors:  Ranjit K Goudar
Journal:  Drugs       Date:  2007       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.